Learning from Mistakes in a Pandemic, Aspiring to Make Better Decisions Each Day

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Vaccination and the Delta Variant: Four Steps Forward, Two Steps Back
Is EQRx an Existential Threat to the Biopharma Industry?
Why We Need mRNA Vaccines in Africa, and For All Who Are Immunocompromised
One-and-Done Gene Editing: A Feature or Flaw?